ERBB2 and breast cancer: Lastly, as ongoing clinical trials explore de-escalation strategies to reduce treatment-related toxicities for patients63,64, efforts should be made to ensure that these approaches are implemented equitably to help close the persisting racial and ethnic gaps in HER2-positive BC care and outcomes.